Johnson & Johnson (JNJ) is a publicly traded drug manufacturers - general business based in the US which employs around 138,200 staff. Johnson & Johnson is listed on the NYSE and traded in US dollars. Its current price of $234.54 is 1.2% down on its price a month ago ($237.28).
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.
We currently don't have that product, but here are others to consider:
How we picked theseTo make comparing even easier we came up with the Finder Score. Costs, features, ease and range of investments across 30+ platforms are all weighted and scaled to produce a score out of 10. The higher the score the better the platform – simple.
Read the full methodologyAll investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Review technicals and fundamentals to help you determine if now's a good time for you to invest.
View Johnson & Johnson's price performance, share price volatility, historical data and technicals.
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Historical closes compared with the last close of $234.54
| 1 week (2026-04-10) | -1.64% |
|---|---|
| 1 month (2026-03-17) | -1.15% |
| 3 months (2026-01-17) | 7.26% |
| 6 months (2025-10-17) | 21.38% |
| 1 year (2025-04-17) | 48.94% |
| 2 years (2024-04-17) | 62.01% |
| 3 years (2023-04-17) | 45.67% |
| 5 years (2021-04-17) | 44.56% |
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Johnson & Johnson P/E ratio, PEG ratio and EBITDA.
Johnson & Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Johnson & Johnson's shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of March 2025 (25.37). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Johnson & Johnson's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
Johnson & Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6679. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson & Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Johnson & Johnson's PEG ratio in relation to those of similar companies.
Johnson & Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $34.1 billion (£25.2 billion).
The EBITDA is a measure of Johnson & Johnson's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Find out the best care home shares along with the pros and cons of investing in this grey-pound-fuelled sector.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
Ever wondered how to buy shares in Eli Lilly and Company? We explain how to invest in Eli Lilly in the UK along with platforms for buying stock.
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
Ever wondered how to buy shares in Walgreens? We explain how and compare a range of providers that can give you access to many brands, including Walgreens.
Ever wondered how to buy shares in Medtronic? We explain how and compare a range of providers that can give you access to many brands, including Medtronic.
Ever wondered how to buy shares in AstraZeneca? We explain how and compare a range of providers that can give you access to many brands, including AstraZeneca.
Learn more about GSK’s recent performance and where you can buy GSK shares. We also run through a helpful checklist for anyone looking to invest.
Ready to compare platforms?